Clinical trialNCT05090358Active, not recruitingPhase 2Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment15Breast CancerBreast Cancer Stage IVMetastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sherry Shen, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (limited Protocol Activity)
Commack, New York, United States
Memorial Sloan Kettering Westchester (all Protocol Activities)
East White Plains, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Weill Cornell Medical College (data Collection & Data Analysis)
New York, New York, United States
Memorial Sloan Kettering Nassau (limited Protocol Activities)
Uniondale, New York, United States
Ohio State University (data Collection & Data Analysis)
Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Alpelisib →Canagliflozin →Fulvestrant →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Oct 2021
Primary completion: 8 Oct 2027
Completion: 8 Oct 2027
Last update posted: 11 Aug 2026
Registered enrollment: 15
Registry id: NCT05090358

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.